Mosaic ImmunoEngineering Inc. Annual Report Summary

I’ve been digging into the latest filing for Mosaic ImmunoEngineering Inc. to help you understand where the company stands. Think of this as a "no-nonsense" summary of their 2025 performance.

1. What does this company do?

Mosaic is a biotech startup currently in the "research and hunt" phase. They do not have a product to sell yet and are focused on identifying and licensing promising cancer-treatment technologies. They reported $0 in revenue this year, as their primary focus is on managing cash and securing new assets.

2. The Big Story: A Company in Transition

The company is currently resetting its business model. Their previous major license—the cowpea mosaic virus (CPMV) platform—ended in March 2024, leaving the company without an active project. They are actively searching for new technology to build a pipeline. While they explored a potential deal with Oncotelic Therapeutics for cancer-fighting tech and AI tools, that agreement expired in June 2025 without a final contract. Management is currently pursuing other opportunities to establish a new foundation for growth.

3. Financial Health: The "Going Concern" Warning

The company’s financial position is extremely limited. As of the last report, they held less than $100,000 in cash while carrying significant debts. They have formally stated that they do not have sufficient capital to fund operations for the next 12 months. Because of this, they are operating as a "going concern," which indicates that their ability to continue as a business depends entirely on their success in raising new capital from investors.

4. Key Risks: Why this is a "Speculative" Investment

If you are looking at this stock, be aware of these high-stakes risks:

• Survival Risk: With cash reserves near zero, the company faces an immediate need for funding. If they cannot secure new capital in the near term, they may be forced to cease operations.
• The "Empty Pipeline" Problem: The company currently has no active development programs or products undergoing regulatory review. They are essentially starting from scratch.
• Dilution: Because they lack revenue, the company must rely on selling more stock to fund future deals. This process typically involves issuing large amounts of new shares, which reduces the ownership percentage and value of existing shares.
• OTC Volatility: This stock trades on the OTC Pink sheets and experiences very low trading volume. This can lead to significant price swings, making it difficult to buy or sell shares at your target price.

5. Future Outlook

The company’s future is tied to its ability to secure a new, "transformative" medical asset. While management is actively searching for new technology to license, they are doing so with limited resources and no current products.

The Bottom Line: This is a high-risk investment in a company currently searching for a viable business path. With no revenue, no active products, and a critical need for cash, the company remains in a state of extreme uncertainty. For most investors, the risks are significant, and the potential for a total loss of investment remains high until the company can demonstrate a sustainable business model.